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Our recent gene expression profiling analyses demonstrated
thatWnt2 is highly expressed in Flk1 cells, which serve as com-
mon progenitors of endothelial cells, blood cells, and mural
cells. In this report, we characterize the role of Wnt2 in meso-
derm development during embryonic stem (ES) cell differentia-
tion by creating ES cell lines in which Wnt2 was deleted.
Wnt2/ embryoid bodies (EBs) generated increased numbers
of Flk1 cells and blast colony-forming cells compared with
wild-type EBs, and had higher Flk1 expression at comparable
stages of differentiation. Although Flk1 cells were increased,
we found that endothelial cell and terminal cardiomyocyte dif-
ferentiation was impaired, but hematopoietic cell differentia-
tion was enhanced and smooth muscle cell differentiation was
unchanged inWnt2/EBs. Later stageWnt2/EBs had either
lower or undetectable expression of endothelial and cardiac
genes comparedwithwild-type EBs. Consistently, vascular plexi
were poorly formed and neither beating cardiomyocytes nor
-actinin-staining cells were detectable in later stage Wnt2/
EBs. In contrast, hematopoietic cell gene expression was up-
regulated, and the number of hematopoietic progenitor col-
onies was significantly enhanced in Wnt2/ EBs. Our data
indicate that Wnt2 functions at multiple stages of develop-
ment during ES cell differentiation and during the commit-
ment and diversification ofmesoderm: as a negative regulator
for hemangioblast differentiation and hematopoiesis but
alternatively as a positive regulator for endothelial and ter-
minal cardiomyocyte differentiation.
Embryonic stem (ES)2 cells have considerable potential for
use in cellular therapies for many human diseases or disorders.
However, manipulating the differentiation of pluripotent cells
into a desired cell type is difficult to control. Therefore, efforts
have been directed toward understanding the molecular and
cellular mechanisms for maintaining ES cell pluripotency as
well as for ES cell fate determination and lineage specification.
Under appropriate culture conditions, ES cells will spontane-
ously differentiate and form embryoid bodies (EBs) that reca-
pitulate the differentiation program of normal embryonic
development. This in vitro experimental model is widely used
to study mesoderm development, including the hematopoietic
system, vascular endothelial cells, and cardiomyocytes (1–4).
Murine hematopoietic and endothelial cell development
begins in the yolk sac mesoderm at approximately day 7.5 of
gestation and is marked by establishment of blood islands (5,
6). The close physical relationship between these two cell
populations within blood islands has led to a widely accepted
hypothesis that a common precursor for both hematopoietic
and endothelial cells exists, the hemangioblast (7, 8). The
receptor for vascular endothelial growth factor (VEGF), fetal
liver kinase-1 (Flk1), is an early molecular marker for
hemangioblasts (9–12). Blast colony-forming cells (BL-
CFCs) derived from EBs can generate hematopoietic and
endothelial cell lineages, and represent the long-hypothe-
sized hemangioblast (13, 14). Flk1 cells may also give rise to
smooth muscle cells (SMC) and cardiomyocytes under
appropriate culture conditions (15–17).
Wnts are paracrine/autocrine signaling molecules that have
been implicated in many aspects of normal development.
CanonicalWnt signaling acts through-catenin andT-cell fac-
tor/lymphoid enhancer factor transcriptional factors that reg-
ulate target gene expression (reviewed in Refs. 18 and 19).
Developmental Wnt signaling is active during embryogenesis
in the cardiac crescent and in endothelial cells during intraem-
bryonic angiogenesis (20). Wnt ligands, receptors, and inhibi-
tors are expressed by vascular cells and participate in both nor-
mal and pathologic vessel growth, yet the key players in these
processes and their roles are not yet identified (reviewed in Ref.
21).Wnt signaling also participates in hematopoiesis by provid-
ing proliferative signals for immature hematopoietic progeni-
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tors and promoting the self-renewal of hematopoietic stem
cells (22, 23).
Among the various Wnts, Wnt2 is localized to sites within
the heart, vasculature, and associated mesoderm during devel-
opment, making it a likely candidate to regulate mesoderm dif-
ferentiation and subsequent hematovascular development (24,
25). Wnt2/ mice have been generated and analyses of these
mice indicate that Wnt2 is required for proper vascularization
of extraembryonic tissues, although a complete assessment of
hematovascular developmentwas not performed (25). Remark-
ably, our inductive microarray studies indicate that Wnt2 is
among themost highly up-regulated genes in Flk1 cells during
EB differentiation, suggesting that Wnt2 is the key Wnt signal
for coordination of hemangioblast differentiation from primi-
tive mesoderm. To extend these studies, we established ES cell
lines carrying targeted mutations for Wnt2 to characterize
mesoderm differentiation in EBs. Wnt2 plays critical roles in
the commitment and diversification of mesoderm, acting as a
positive signal for endothelial and cardiomyocyte differentia-
tion but inhibiting hemangioblast differentiation and hemato-
poiesis, suggesting that manipulation of Wnt2 signals may be
useful to tune stem cell differentiation for vascular applications.
EXPERIMENTAL PROCEDURES
Generation of Wnt2 Mutant ES Cell Lines and ES Cell
Culture—The R1 ES cell line heterozygous for theWnt2 muta-
tion (Wnt2/neo) was previously described (25). The hygromy-
cin (hygro-) targeting vector was constructed using strategies
(outlined in Fig. 1) similar to that for the Neo-targeting vector
(25). The hygro-targeting construct was electroporated into
Wnt2/neo ES cells. Homologous recombination occurring
between the hygro-targeting vector and the wild-type allele
replaces exon 2 ofWnt2with the PGK-hygro cassette, resulting
in a compound heterozygote (Wnt2hygro/neo). Hygro-resistant
ES cell colonies were screened by PCR with a primer set indi-
cated by arrows in Fig. 1. PCR-positive colonies were grown in
G418-containing media and the subsequent G418-resistant
colonies were analyzed by Southern blotting to confirm homol-
ogous recombination. Genomic DNA digested with SacI was
probed by a 0.5-kb 3 external fragment (indicated by a bar in
Fig. 1). Of 117 colonies analyzed, two Wnt2hygro/neo (hereafter
referred to as Wnt2/) ES cell colonies (G3 and D8) were
obtained, and G3 was used in all of following experiments,
although cells derived from both clones behaved identically in
our assays. Wnt2/, Wnt2/, and Wnt2/ ES cells were
maintained on mitomycin-treated feeder cells in the presence
of LIF. Cells were transferred to gelatin plates with 5637 cell-
conditionedmedium as a source of LIF and passaged two times
to remove feeder cells before the onset of differentiation. In
vitro differentiation was performed as previously described
(26).
FACS Analysis and Immunostaining—EBs were dissociated
with trypsin and stained with phycoerythrin-conjugated anti-
Flk1 monoclonal antibody (BD Pharmingen) for FACS analysis
of Flk1 expression. Cells were analyzed on a FACScan (BD Bio-
sciences) with Cytomation Summit software. For immuno-
staining, EBs were fixed in ice-cold methanol:acetone (50:50),
blocked, and incubated with primary antibodies followed by
appropriate secondary antibodies. The primary antibodies used
were rat anti-PECAM-1 (MEC13.3, BD Pharmingen), mouse
anti--actinin (EA-53, Sigma), andmouse anti--smoothmus-
cle actin (1A4, Sigma). The secondary antibodies used were
Alexa 488-conjugated goat anti-rat IgG and Alexa 568-conju-
gated goat anti-mouse IgG (Molecular Probes).
Reverse Transcriptase-Polymerase Chain Reaction—Semi-
quantitative RT-PCR was performed as previously described
(27). Quantitative RT-PCR (qRT-PCR) was performed with an
Applied Biosystems 7700 Sequence Detection System using
total RNApurified fromEBs. Amplificationswere performed in
triplicate for 40 temperature cycles. Copy numbers of the
mRNA template in each sample were calculated using the ABI
Sequence Detector Software.
Hemangioblast Colony and Hematopoietic Progenitor Cell
Assays—EBs were generated as described with some modifica-
tion (28). Briefly, ES cells were plated in 6-well dishes in differ-
entiation medium containing Iscove-modified Dulbecco’s
medium, 15% differentiation fetal calf serum (StemCell Tech-
nologies, Vancouver, BC, Canada), glutamine (2 mM), mono-
thioglycerol (450M), holo-transferrin (500g/ml), and ascor-
bic acid (50 g/ml). ES cells were plated at 50,000 cells/ml for
day 4 EBs or 5,000 cells/ml for days 5–6 EBs, with an additional
5% protein-free hybridoma medium (Invitrogen).
BL-CFCs, erythroid, andmyeloid colonies were generated as
described (28, 29). For BL-CFC assays, day 4 EB cells were
plated at 50,000 cells/ml in 1%methylcellulose with 10% differ-
entiation fetal calf serum, 25% D4T cell-conditioned media
(13), c-kit ligand (1% conditioned medium), and VEGF (5
ng/ml, R & D Systems). Days 5 and 6 EB cells were plated at
50,000 cells/ml in 1%methylcellulose with 15% plasma-derived
serum (Animal Technologies, Antech, TX), erythropoietin (20
units/ml) (Amgen, Thousand Oaks, CA), kit ligand (1%),
thrombopoietin (2% conditioned medium), transferrin (500
g/ml), and 5% PFHM-II for primitive and definitive erythroid
colony assays, or with 15% plasma-derived serum, erythropoi-
etin (20 units/ml), c-kit ligand (1%), thrombopoietin (2%), 5%
hybridoma medium, interleukin-3 (1% conditioned medium),
and interleukin-11 (5 ng/ml, R & D Systems) for myeloid and
mixed colony assays. Primitive anddefinitive erythroid colonies
were counted after 4–6 days, and myeloid and mixed colonies
were counted after 7–10 days.
Production of ConditionedMedia—We used aDrosophila S2
cell line expressingWnt2 and a control S2 cell line, which were
generous gifts from Roel Nusse (Stanford University). Wnt2 S2
cells were cultured in Schneider’s media supplemented with
10% fetal bovine serum under selection with hygromycin (125
g/ml) for 2–3 passages before collection of media.
RESULTS
Increased Numbers of Flk1 Cells and BL-CFC Frequency in
Wnt2-deficient EBs—In a previously described set of gene
expression profiling experiments (comparing gene expression
profiles in Flk1 cells versus Flk1 cells at different stages dur-
ing ES cell in vitro differentiation), we found thatWnt2 expres-
sion was much higher in Flk1 cells in comparison with Flk1
cells (27). This expression pattern was confirmed by RT-PCR
analysis, which indicated that Wnt2 was expressed in early
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Flk1 cells and undetectable in Flk1 cells, and was expressed
in later stage Flk1 cells at much lower levels compared with
Flk1 cells (Fig. 1A). In a hierarchical clustering analysis for
differentially expressed genes in Flk1 versus Flk1 cells over
time, Wnt2 was clustered closely with Flk1 and other genes
related to mesoderm development such as Bmp4, Tgfb2,
Hand1, and Gata6 (Fig. 1B).
Based on these observations, we hypothesized that Wnt2
may participate in developmental events within the mesoderm
that determine vascular and/or hematopoietic differentiation.
Therefore, we initially evaluated the effects of Wnt2 on the
early development of Flk1 cells by creating Wnt2 ES cells
(Fig. 1,C andD).We compared these cells toWnt2/ ES cells,
similar to approaches that have been previously described for
other targeted alleles in this system (10), because the Wnt2
and Wnt2/ ES cells have been through identical selection
processes andWnt2/ ES cells lacking a selectionmarker can-
not be brought through the same selection process. Neverthe-
less, Wnt2/ ES cells differentiate in all of the lineages we
characterize in these experimentswith kinetics thatmimic uns-
electedWnt2/ ES cells (see below), indicating that a pheno-
type due to heterozygosity for Wnt2 is either absent or
extremely subtle. All the ES cells used in these studies main-
tained a highly undifferentiated state, as determined by Nanog
expression and germ-line competency (data not shown).
Days 3–4 (72, 82, and 96 h)Wnt2/ andWnt2/ EBs were
analyzed by FACS for their potential to generate Flk1 cells. In
Wnt2/EBs, the Flk1 cell populationwas initially detected at
around 82 h and it progressively increased in abundance to
about 30% at 96 h (Fig. 2, A and B). These kinetics match those
of Wnt2/ EBs found in our previous studies (27), arguing
against a significant phenotype due to lack of a single Wnt2
allele. In contrast, Wnt2/ EBs generated Flk1 cells in
increased numbers and with accelerated kinetics. The Flk1
cell population was detected as early as 72 h and increased dra-
matically to about 50% at 96 h inWnt/ EBs. Consistent with
these observations, Flk1 mRNA was more abundantly
expressed in days 3.5 and 4 EBs inWnt2/ ES cells as well (Fig.
2C). These experiments indicate that Wnt2 coordinates events
within primitive cell populations that determine when and how
mesoderm-derived cells such as those expressing Flk1 appear.
To assess the specificity ofWnt2 effects onmesoderm differ-
entiation, we analyzed the expression of genes associated with
ES cells and the three germ layer lineages (ectoderm,
FIGURE 1.Wnt2 expression analyses and targetedmutation of theWnt2 locus to generateWnt2hygro/neo (Wnt2/) ES cell lines.A, RT-PCR confirmation
of Wnt2 expression pattern in Flk1 versus Flk1 cells at the indicated times during ES cell differentiation. B, hierarchical clustering analysis for differentially
expressed genes in Flk1 versus Flk1 cells during ES cell differentiation indicating that Wnt2 is closely clustered with Flk1 and other mesoderm-associated
genes. The color scale ranges from green for log ratio2 to red for log ratio2. C, schematic representation of theWnt2 gene-targeting strategy. The hygro
targeting vector, the wild-typeWnt2 locus including exons 1–3, the original neo-targetedWnt2 allele (25), and the hygro-targetedWnt2 allele are shown. PCR
screening primers (arrows) and 3-external probe (horizontal bar) are indicated. Digestion of genomicDNAwith SacI and hybridizationwith a 3-probe identify
different band sizes: 9.0 kb for the wild-type allele, 8.0 kb for the neo allele, and 10 kb for the hygro allele, respectively. D, verification of homologous
recombination occurring at the wild-type allele in ES cell clones by Southern blotting. The size of the DNA band is indicated in kb.
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endoderm, andmesoderm) inWnt2/ andWnt2/ EBs dur-
ing different stages of ES cell differentiation (Table 1, Fig. 2C).
Oct4, which is expressed in the inner cell mass and in undiffer-
entiated ES cells, was down-regulatedwith similar kinetics dur-
ing differentiation in both Wnt2/ and Wnt2/ EBs. The
mesodermmarker gene,Brachyury (T), was expressed at higher
levels at day 3 in Wnt2/ EBs (18.8-fold increase compared
with mRNA levels in undifferentiated cells) compared with
Wnt2/ EBs (2.9-fold increase), and was also down-regulated
more rapidly in Wnt2/ EBs. Flk1 and another T-box gene
that has been implicated in yolk sac development, Tbx3 (31),
were similarly up-regulated early, but greatly reduced at later
stages of Wnt2/ EBs compared with Wnt2/ EBs. In con-
trast to thosemesoderm-associated genes, no significant differ-
FIGURE 2. Altered developmental potential of Flk1 cells and BL-CFCs inWnt2/ ES cells. A, kinetic analysis of flk1 expression by FACS inWnt2/ and
Wnt2/ EBs at 72, 82, and 96 h during ES cell differentiation. Representative results from three experiments are shown. B, quantitative results of three
independent experiments performed as described in A are shown. Data representmean S.E. *, p 0.05 comparedwithWnt2/ EBs. C, expression analyses
of the indicatedgenes (genes associatedwith ES cells and the threegerm layer lineages) by RT-PCR inWnt2/ andWnt2/ EBs at different timepoints during
ES cell differentiation are shown. Hprt was included as a loading control. D, hemangioblast (BL-CFC) potential of Wnt2/ and Wnt2/ EBs at day 4 of
differentiation (n 3). Data shown are mean S.E. *, p 0.05 compared with Wnt2/ EBs. Representative images of a hemangioblast (BL-CFC) colony and
a secondary EB are shown.
TABLE 1
Quantitative RT-PCR analysis of indicated mRNAs over time inWnt2/ andWnt2/ EBs (n 3 per condition)
0 Days 2 Days 3 Days 3.5 Days 4 Days 6 Days 8 Days 10 Days
Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E.
Wnt2/
Flk1 1.0 0.0 1.0 0.2 1.4 0.3 2.5 0.7 18.3 2.1 24.9 3.7 14.4 5.3 9.3 3.4
T 1.0 0.0 2.1 0.1 2.9 0.5 6.9 1.2 16.7 3.1 9.1 2.0 1.4 0.2 1.1 0.2
Oct4 3.2 0.7 3.9 0.8 3.8 0.5 3.6 0.4 3.6 0.8 3.3 0.6 1.2 0.3 1.0 0.0
Wnt2/
Flk1 1.0 0.0 1.1 0.2 2.1 0.4 21.3 5.3 37.7 4.8 31.6 3.9 28.5 1.9 6.9 2.0
T 1.0 0.0 1.9 0.4 18.8 1.3 22.2 3.7 15.0 1.8 1.8 0.2 1.6 0.3 1.3 0.1
Oct4 3.8 1.0 4.0 0.6 3.3 0.6 3.1 0.7 3.0 0.6 2.6 0.5 1.1 0.2 1.0 0.0
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ence was found for the ectoderm-associated marker neural cell
adhesion molecule or the endoderm-associated gene -feto-
protein inWnt2/ EBs compared withWnt2/ EBs. There-
fore, the effects of Wnt2 on ES cell differentiation appear to be
largely restricted to themesoderm, and deficiency ofWnt2 pro-
motes the early differentiation of mesoderm and dysregulates
its terminal differentiation.
The BL-CFC is an in vitro equivalent of the hemangioblast
and is able to generate primitive and definitive hematopoietic
cells as well as endothelial cells when cultured with appropriate
growth factors (13, 14). To further confirm the effects of Wnt2
on the differentiation of the early mesoderm-associated
hemangioblast, we performed hemangioblast colony assays.
Because maximum numbers of BL-CFCs are reached between
days 3.25 and 4.25 during EBdifferentiation (13), we plated cells
of Wnt2/ and Wnt2/ EBs at day 4.0 in methylcellulose
cultures in the presence of VEGF and c-kit ligand. BL-CFCs can
be readily identified morphologically in distinction to second-
ary EBs (Fig. 2D). Compared with
Wnt2/ ES cells, the generation of
BL-CFCs from Wnt2/ ES cells
was significantly enhanced. The
production of secondary EBs from
Wnt2-deficient cells was slightly,
but not significantly, decreased. The
increase in BL-CFC frequency in
Wnt2-deficient ES cells coincides
closely with the increase of Flk1
cells by FACS analysis (Fig. 2A).
Taken together, these experiments
indicate that deficiency of Wnt2
enhances the differentiation and
proliferation of ES cells to
hemangioblasts.
Wnt2Affects theDifferentiation of
EBs to Endothelial Cells but Not
SMC—Because Flk1 hemangio-
blasts serve as vascular progenitors,
we next investigated the role of
Wnt2 in vascular development. Flk1
expression levels were reduced in
Wnt2/ EBs at day 10 (Fig. 2C),
which coincides with attainment of
the mature vascular phenotype and
primitive vascular plexus formation
in EBs (26), indicating the possible
impairment of terminal vascular
development. Therefore, we performed RT-PCR for endotheli-
al-specific genes including PECAM, VE-cadherin, and Tie2 at
different time points during differentiation in Wnt2/ and
Wnt2/ EBs (Table 2, Fig. 3A). These three endothelial mark-
ers were up-regulated with similar kinetics during differentia-
tion over time (from day 6 to 10) in Wnt2/ EBs, with peak
levels at day 10 when the endothelial phenotype is maturing.
However, this expression patternwas reversed inWnt2/EBs,
with peak levels 2-fold or greater above those seen inWnt2/
EBs in day 6 EBs and levels less than half of those seen in
Wnt2/ EBs at day 10 (Table 2). To further confirm the effect
of Wnt2 on endothelial development, day 8 EBs were stained
with a PECAM antibody to demarcate the vascular network. In
Wnt2/ EBs, well organized vascular plexi were formed,
whereas only a few, scattered PECAM-positive cells were seen
inWnt2/ EBs (Fig. 3B). These data indicate that the terminal
differentiation of ES cells to endothelial cells is impaired in
Wnt2/ EBs.
FIGURE 3. The impact of Wnt2 deficiency on the commitment of ES cells to endothelial, SMC, and car-
diomyocyte lineages. A, expression analyses of the indicated genes by RT-PCR inWnt2/ andWnt2/ EBs
at different time points during ES cell differentiation are shown. Genes are grouped according to their speci-
ficity for EC, SMC, and cardiomyocyte lineages as indicated on the left. Hprt was included as a loading control.
B, immunostaining for PECAM, SM -actin, and -actinin in Wnt2/ and Wnt2/ EB at day 8 during ES cell
differentiation. Specific antibodies stained images as shown on the top and corresponding phase-contrast
images are on the bottom. Experiments were repeated 3 times independently.
TABLE 2
Quantitative RT-PCR analysis of endothelial mRNAs over time inWnt2/ andWnt2/ EBs (n 3 per condition)
0 Days 2 Days 3 Days 3.5 Days 4 Days 6 Days 8 Days 10 Days
Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E.
Wnt2/
PECAM1 3.8 0.5 1.9 0.4 1.4 0.1 1.2 0.2 1.0 0.0 3.0 0.6 3.2 0.4 4.6 0.9
VE-cad 1.0 0.0 1.0 0.1 1.2 0.1 1.1 0.1 1.2 0.2 10.8 2.1 14.0 1.9 17.9 2.1
Tie2 1.8 0.1 1.4 0.1 1.2 0.2 1.0 0.0 1.1 0.1 10.1 3.4 16.3 1.7 28.1 2.9
Wnt2/
PECAM1 4.3 0.5 1.6 0.2 1.6 0.3 1.2 0.2 1.0 0.0 5.6 1.0 3.9 0.8 1.7 0.3
VE-cad 1.0 0.0 1.2 0.2 1.2 0.2 1.2 0.1 2.0 0.2 24.3 3.6 19.9 2.8 9.8 3.0
Tie2 2.0 0.1 1.5 0.1 1.1 0.1 1.0 0.0 1.9 0.5 24.8 3.5 17.3 1.9 6.1 1.3
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SMC are periendothelial cells that are essential for vascular
maturation and stabilization. Recent studies have shown that
Flk1 cells in EBs may also give rise to SMC under appropriate
conditions (15). Therefore, we also performed expression anal-
yses using molecular markers for SMC, including transcription
factors involved in regulation of SMC differentiation (Mef2c
and serum response factor) and contractile proteins smooth
muscle (SM) -actin, SM 22, and SMmyosin heavy chain, the
latter of which is probably themost SMC-restricted gene. All of
these markers showed very similar expression patterns, and
no consistent differences were detected between Wnt2/
andWnt2/ EBs during ES cell differentiation (Fig. 3A). To
further confirm this observation, day 8 EBs were stained with
a SM -actin antibody. In support of the gene expression
analyses, we saw no difference for SM -actin staining
between Wnt2/ and Wnt2/ ES cells (Fig. 3B). There-
fore, Wnt2 is necessary for hemangioblast development as
well as further differentiation to endothelial cells but prob-
ably not for SMC differentiation, whether or not these SMCs
derive from Flk1 cell populations.
Wnt2-deficient EBs Have Impaired Cardiomyocyte Dif-
ferentiation—Cardiomyocytes are also mesoderm-derived
and recent data indicate that Flk1 cells may give rise to some
populations of cardiomyocytes (16, 17). In addition, Wnt2
expression is detected in precardiac mesoderm and derived
structures such as the pericardium from as early as 7.5 days
post-conception forward (24, 25), and Wnt signaling is gener-
ally required for normal cardiogenesis (32, 33). Therefore, we
investigated whether Wnt2 had any effect on in vitro cardiom-
yocyte differentiation in the ES differentiation model, where
the differentiation and formation of beating cardiomyocytes
occurs in later stage EBs (days 8 and 10). First, we analyzed
Wnt2/ and Wnt2/ EBs at different time points for their
expression of specific cardiomyocyte markers: the cardiogenic
transcription factors, GATA4 and Nkx2.5, and cardiac-specific
proteins, - and -myosin heavy chain and ventricular-specific
myosin light chain-2v. In Wnt2/ EBs, these genes were all
up-regulated over time during differentiation (Table 3, Fig. 3A).
In comparison, GATA4 and Nkx2.5 were expressed, but at
reduced levels, after day 6 inWnt2/ EBs. Moreover, whereas
we readily detected greater than 20-fold induction of cardiac-
specific proteins- and-myosin heavy chain andmyosin light
chain-2v in laterWnt2/ EBs (days 6 to 10), minimal quanti-
tative induction of these genes was detected in later Wnt2/
EBs (Table 3). Consistent with a major defect in the terminal
stages of cardiomyocyte differentiation, we did not observe the
formation of spontaneously beating clusters in any Wnt2/
EBs after 8–10 days culture, whereas these beating clusters
were easily detected in all Wnt2/ EBs. Similarly, when we
stained day 8 EBs with an antibody for -actinin, a marker for
cardiomyocytes, we found -actinin-positive cardiomyocytes
in Wnt2/ EBs but no stained cells were found in Wnt2/
EBs (Fig. 3B). Taken together, these data indicate that Wnt2
may have a subtle regulatory role in early stages of cardiomyo-
cyte differentiation, terminal cardiomyocyte differentiation in
EBs is critically dependent on Wnt2.
Wnt2Deficiency Affects the Developmental Potential of Prim-
itive and Definitive Hematopoiesis—Because Wnt2 deficiency
promotes the differentiation of hemangioblasts but impairs
their terminal differentiation to endothelial cells, we ques-
tioned the fate of the increased number of hemangioblasts dur-
ing early mesoderm differentiation from Wnt2/ ES cells.
Because Flk1 cells or hemangioblasts also give rise to primitive
and definitive hematopoietic cells (11, 12), we examined
whether Wnt2 contributed to hematopoiesis as well. We ini-
tially performed expression analyses of hematopoietic genes,
including three hematopoietic transcriptional factors (EKLF,
GATA1, and Scl/Tal1), the embryonic and adult hemoglobin
genes (-H1 and -major), and the hematopoietic cell surface
marker tyrosine phosphatase CD45. -H1 and -major globin
genes are used as markers for erythroid cells and CD45 is a
marker for nucleated hematopoietic cells.We observed that the
expression of all three hematopoietic cell-specific transcrip-
tional factors, EKLF, GATA1, and Scl/Tal1, were more highly
expressed in days 6 and 8 Wnt2/ EBs (Table 4, Fig. 4A).
Similar expression patterns were obtained for the other hema-
topoietic cell genes.-H1 expressionwas up-regulated in days 6
and 8Wnt2/EBs.-major andCD45 expressionwere greatly
increased in days 8 to 10Wnt2/ EBs (Table 4). Notably, day
10 is around the time when definitive hematopoiesis occurs in
this system.The expression pattern of these hematopoietic cell-
specific genes suggests that hematopoietic cell differentiation
and specification from hemangioblasts is expanded or acceler-
ated in the absence of Wnt2.
To confirm the results obtained from the gene expression
analyses, we performed hematopoietic progenitor cell assays,
which provide an easy and direct way to assess primitive and
definitive hematopoiesis. On days 5 and 6 of differentiation,
TABLE 3
Quantitative RT-PCR analysis of cardiomyocyte mRNAs over time inWnt2/ andWnt2/ EBs (n 3 per condition)
0 Days 2 Days 3 Days 3.5 Days 4 Days 6 Days 8 Days 10 Days
Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E.
Wnt2/
GATA4 1.0 0.0 1.0 0.0 1.2 0.1 1.8 0.4 3.1 0.7 3.0 0.4 2.8 0.3 2.9 0.4
Nkx2.5 1.0 0.0 1.4 0.2 1.1 0.2 1.2 0.2 1.3 0.2 3.0 0.7 2.8 0.6 3.0 0.5
-MHC 1.1 0.2 1.1 0.1 1.0 0.1 1.0 0.0 1.2 0.4 3.9 1.1 19.7 4.2 27.3 3.6
-MHC 2.1 0.3 2.2 0.3 1.7 0.4 1.4 0.6 1.0 0.0 2.8 0.4 14.7 3.1 23.6 3.3
MLC-2v 1.3 0.1 1.0 0.1 1.0 0.2 1.0 0.1 1.0 0.0 1.4 0.6 1.9 0.2 4.0 0.5
Wnt2/
GATA4 1.0 0.0 1.2 0.2 1.8 0.3 2.0 0.3 3.5 0.5 2.4 0.6 2.2 0.2 2.0 0.4
Nkx2.5 1.0 0.0 1.5 0.1 1.0 0.0 1.0 0.1 1.4 0.2 1.4 0.2 1.5 0.3 1.3 0.1
-MHC 1.3 0.2 1.0 0.1 1.1 0.2 1.0 0.0 1.3 0.3 1.3 0.1 1.2 0.1 1.1 0.3
-MHC 2.6 0.6 2.0 0.4 1.6 0.2 1.3 0.1 1.0 0.0 1.7 0.2 1.7 0.4 1.9 0.2
MLC-2v 1.5 0.3 1.3 0.3 1.0 0.1 1.1 0.2 1.0 0.0 1.0 0.1 1.1 0.2 1.3 0.2
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primary EBs were collected and dissociated to single cells,
and then replated into culture conditions supporting either
erythroid or myeloid cell growth, respectively. Colonies
including primitive erythroid (EryP), definitive erythroid
(EryD), mixed (CFC-mix), and other committed myeloid
progenitors (CFC, mostly granulocyte-macrophage progen-
itors) were counted. Maximal numbers of hematopoietic
progenitor colonies were obtained at day 5 and significantly
greater differentiation to both erythroid and myeloid pro-
genitor colonies was observed inWnt2/ EBs (Fig. 4, B–E).
Compared with day 5 EBs, a dramatic decrease in all hema-
topoietic progenitor colonies was found in day 6 EBs. How-
ever, the number of those colonies was still increased in day
6 Wnt2/ EBs when compared with Wnt2/ EBs at the
same time. These progenitor assay results, in combination
with our gene expression analyses, provide strong evidence
that deficiency in Wnt2 results in expansion or acceleration
of hematopoietic cell differentiation.
TABLE 4
Quantitative RT-PCR analysis of hematopoietic mRNAs over time inWnt2/ andWnt2/ EBs (n 3 per condition)
0 Days 2 Days 3 Days 3.5 Days 4 Days 6 Days 8 Days 10 Days
Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E. Mean S.E.
Wnt2/
CD45 1.0 0.0 1.0 0.1 1.0 0.0 1.0 0.1 1.1 0.2 1.2 0.2 1.5 0.4 8.9 2.0
-major 1.0 0.0 1.0 0.2 1.1 0.2 1.3 0.2 1.5 0.3 10.5 0.8 8.7 2.1 8.5 1.9
GATA1 6.1 0.4 1.3 0.3 1.2 0.3 1.0 0.0 3.0 0.5 13.1 0.9 3.8 0.3 3.3 0.9
Wnt2/
CD45 1.0 0.0 1.0 0.2 1.0 0.1 1.1 0.2 1.0 0.2 1.1 0.1 8.0 1.2 19.4 3.1
-major 1.0 0.0 1.1 0.3 1.0 0.3 1.2 0.4 1.2 0.3 32.8 5.0 27.2 3.5 11.7 2.3
GATA1 5.3 0.7 1.5 0.1 1.0 0.0 1.2 0.3 28.9 4.4 16.7 1.6 15.1 1.9 5.8 0.7
FIGURE 4. The impact ofWnt2deficiency on thehematopoietic differentiationpotential of ES cells.A, expression analyses of the indicated genes specific
for hematopoietic cell lineages inWnt2/ andWnt2/EBs asdeterminedbyRT-PCRatdifferent timepoints duringES cell differentiationare shown.Hprtwas
included as a loading control. B–E, hematopoietic progenitor assays for days 5 and 6 Wnt2/ and Wnt2/ EBs. Results shown are mean S.E. from three
independent experiments, cultureswere plated in triplicate. *, p 0.05 comparedwithWnt2/ EBs. B, primitive erythroid colony (EryP) and its representative
image. C, definitive erythroid colony (EryD) and its representative image. D, myeloid colonies, including granulocyte-macrophage (GM), granulocyte only,
megakaryocyte, erythroid-macrophage, and erythroid-megakaryocyte colonies. Image shown is representative of GM colonies. E, mixed hematopoietic
colonies and a representative image are shown.
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Wnt2 Rescues the Phenotypes of Wnt2/ ES Cells—To con-
firm that our observations inWnt2/ ES cells is indeed due to
Wnt2 deficiency, we tested whether addition ofWnt2 to differ-
entiation medium would rescue the failure of endothelial and
cardiomyocyte differentiation. We used conditioned media
from S2 cells expressing Wnt2 (Wnt2-CM) or from control S2
cells (S2-CM) in these experiments, as we have previously
described (27).Wnt2-CMmarkedly increased the development
of both PECAM-() structures and -actinin-positive cells in
day 8Wnt2/ embryoid bodies (Fig. 5), indicating that Wnt2
is indeed required for both endothelial and terminal cardiom-
yocyte differentiation in this system.
DISCUSSION
The experiments presented here define a previously unsus-
pected role for Wnt2 in coordinating development within the
pre-cardiac and hematovascular mesodermal niches in EBs,
which corresponds closelywith its expression in earlymesoder-
mal subpopulations and developing cardiovascular structures
(25). Based on these studies, we have identified specific sequen-
tial regulatory roles for Wnt2 in this differentiation process.
The expansion of hemangioblasts in Wnt2/ EBs indicates
that Wnt2 has a suppressive or coordinating role in initial dif-
ferentiationwithin the hematovascular lineage, and themarked
suppression of terminal cardiomyocyte differentiation in these
EBs suggests that there may be a competitive relationship
between these lineages within the mesoderm, such that Wnt2
favors cardiomyocyte differentiation at the expense of hemato-
vascular development. Subsequently, Wnt2 also has a regula-
tory role in maturation of hemangioblasts, with our experi-
ments in Wnt2/ EBs indicating that Wnt2 is required for
normal endothelial maturation and vascular plexus formation,
but that Wnt2 suppresses early and definitive hematopoietic
differentiation (Fig. 6).
Wnt signaling has been generally associated with several key
steps in vascular development. For example, studies of trans-
genic Wnt/-catenin reporter mice have demonstrated the
activation of canonicalWnt signaling in endothelial cells during
intraembryonic angiogenesis (20), and the requirement ofWnt
signaling for correct vascular patterning and maintenance of
vascular integrity has been confirmed by specific inactivation of
-catenin in endothelial cells (34). Nevertheless, the specific
Wnts and any developmental role that theymay play within the
hematovascular compartment have remained open questions.
Wnt2/ mice are known to have impaired vascularization of
extraembryonic tissues that results in incompletely penetrant
perinatal lethality of mice (25). However, other cardiovascular
defects were not reported in these mice, and until now little
focus has been placed on the role for Wnt2 in hematovascular
development. In retrospect, it is important to consider the pos-
sibility of a broader developmental role forWnt2 thanwhatwas
inferred from these earlier studies. The mice reported in these
studies were outbred, were evaluated at a time when many
FIGURE5.Wnt2-conditionedmedia rescue thephenotypesofWnt2/ES
cell lines. Immunostaining for PECAM and -actinin inWnt2/ EB at day
8 during ES cell differentiation, in the presence of Wnt2-conditioned
media (Wnt2-CM) or control media (S2-CM) for the final 5 days. Specific
antibody stained images are shown on the top and corresponding phase-
contrast images are on the bottom. Experiments were repeated 3 times
independently.
FIGURE 6. Proposedmodel depicting the role of Wnt2 in hemangioblast,
endothelial, cardiomyocyte, SMC, and hematopoietic cell commitment
during ES/EB differentiation. Vertical or horizontal bars and down arrows
indicate the negative effects of Wnt2 seen on the committed mesoderm cell
numbers, and positive () markers and up arrows represent the increase
number of mesoderm progeny.
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molecular markers and provocative studies of cardiovascular
development were not available, and did not undergo a thor-
ough analysis of cardiac morphogenesis or hematopoietic
development. In addition, redundancy or compensation by
other Wnt family proteins (in particular, Wnt5a (35)) coupled
with difficulties in studying Wnt proteins due to the lack of
functional recombinant proteins and antibodies, have ham-
pered our ability to understand which Wnt family members
play key roles in cardiovascular development. The present stud-
ies help to clarify the mechanisms leading to perinatal lethality
inWnt2/mice and indicate a broader specific role for Wnt2
in cardiovascular and hematopoietic development than has
previously been recognized.
Wnt proteins typically act as autocrine factors or have spa-
tially confined paracrine effects (18, 19). Further studies will be
needed to determine which other components of the Wnt sig-
naling pathway act downstream of Wnt2 to mediate its auto-
crine/paracrine effects within the mesodermal-derived com-
partments defined in our studies. Fzd5 is the most likely
candidate receptor forWnt2 in cells with hemangioblast poten-
tial. Fzd5 interacts functionally with Wnt2 when ectopically
expressed, and mice that are null for Fzd5 have defects in both
yolk sac and placental vascularization that overlapwith those of
Wnt2/mice (35). Ishikawa and colleagues (35) did not detect
Wnt2 expression in the yolk sac, and suggested that Wnt2 was
the most likely candidate Wnt to mediate the placental defects
observed in their studies, but that another Wnt might be
responsible for the signaling events that accounted for the yolk
sac hemangioblast defects they observed. However, we found
thatWnt2mRNA is easily detectedwithin the yolk sac (data not
shown), and it is more likely that the partial discordance
betweenWnt2 andFzd5 knock-out phenotypes is due to factors
such as differences in themouse strains used or to complemen-
tation by other Wnts in the yolk sac.
The molecular mechanisms that determine how Wnt sig-
naling affects vascular development are not well character-
ized. -Catenin accumulation has been linked to the rate of
proliferation in endothelial cells (36). VEGF, a potent stim-
ulator for vasculogenesis and angiogenesis, can be regulated
by Wnt/-catenin and is a target gene of Wnt signaling in
cancer (37, 38). Conversely, the GSK3/-catenin signaling
axis can promote angiogenesis in endothelial cells via VEGF
signaling (39). Cox2, another potent stimulator of angiogen-
esis, is up-regulated in vascular cells in response to Wnt
signaling (40). Our recent studies indicate widespread activa-
tion of genes that regulateWnt signaling within the endothelial
lineage as differentiation proceeds and delineate a role forWnt
activation in proliferation of endothelial progenitors (27).How-
ever, the present studies define more precise effects for Wnt/
GSK3/-catenin activation generally, and Wnt2 signaling in
particular, that extend beyond maturing endothelial cells and
indicate precise coordination of multiple events during differ-
entiation of mesoderm-derived tissues that determine early
steps in vascular development.
The consequences ofWnt2 deletion on hematopoietic devel-
opment in our studies are potent and unanticipated. Wnt acti-
vation has varied effects within the hematopoietic compart-
ment: Wnt proteins function as hematopoietic growth factors
and stimulate hematopoietic progenitors in some experiments,
and modulation of Wnt activity affects the ratio of differenti-
ated to mature hematopoietic cells (22, 41). Wnt signaling also
leads to self-renewal of hematopoietic stem cells, preventing
their differentiation and promoting proliferation (23).
Although these data indicate roles for Wnt signaling in imma-
ture hematopoietic progenitors, our data from in vitro differen-
tiation of Wnt2/ EBs suggest that Wnt2 has a specific and
heretofore unanticipated role in hematopoietic cell lineage
commitment.
Wnt2 is also expressed in the heart in adults (24) and in
precardiac mesoderm and derived tissues (25). The present
studies indicate an additional role for Wnt2 during terminal
cardiomyocyte differentiation. Several lines of evidence delin-
eate contributions by Wnt signaling in cardiac development.
Inhibition of Wnt signaling by Dkk-1 induces heart-specific
gene expression in posterior lateral plate mesoderm, and Wnt
signals (Wnt3a and Wnt1) from the neural tube block heart
formation in the adjacent paraxial mesoderm (32, 33). How-
ever, noncanonical Wnt signaling mediated by Wnt11 is
required for heart formation inXenopus embryos (42), and pro-
motes differentiation of both ES cells and circulating progeni-
tors to cardiomyocytes (30, 43). These studies suggest that
canonical Wnt signaling is an inhibitory signal, whereas non-
canonicalWntsmay positively regulate cardiogenesis. Our data
demonstrate that Wnt2 promotes cardiomyocyte differentia-
tion, in contrast with other Wnts that activate the canonical
pathway. This difference suggests that different Wnt ligands
may play different roles during development: whereas Wnt3a
and Wnt1 may provide negative signals, Wnt2 and Wnt11 act
as positive regulators of cardiogenesis. Further studies, perhaps
using compoundmutants inmice, will be needed to explore the
precise roles of these proteins in cardiac differentiation.
In summary, the observations in this report reveal unique
roles for Wnt2 during ES differentiation and fate specification.
Wnt2 functions at multiple stages of development in this
model.Wnt2 is a negative regulator for hemangioblast commit-
ment, and later on, a positive regulator for endothelial cell and
terminal cardiomyocyte differentiation, but a negative regula-
tor for blood cell commitment. Although involvement of Wnt
signaling has been demonstrated in different aspects of meso-
derm development, our report is the first one that suggests that
Wnt2 affects multiple differentiation stages and cell lineages.
These data also support the complexity in cell lineage specifi-
cation and commitment and the need for defined balance of
negative and positive regulators for accurate and reproducible
development.
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